everyone's got an agenda and everyone's frustrated by this action. I was on record saying we'd run after the 2dry. RUN! seems funny to say now.....
outright rude behavior will not be tolerated but someone speaking about their viewpoints of TA and low isn't enough to get me going....
Recent RPRX News
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:10:00 PM
- Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:42:57 PM
- Royalty Pharma to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/13/2024 12:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:01:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:17:01 AM
- Royalty Pharma Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab • GlobeNewswire Inc. • 05/09/2024 10:45:00 AM
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/19/2024 12:15:00 PM
- Royalty Pharma Declares Second Quarter 2024 Dividend • GlobeNewswire Inc. • 04/17/2024 12:15:00 PM
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 02:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:33:43 PM
- Royalty Pharma Reports Q4 and Full Year 2023 Results • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 12:01:30 PM
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 • GlobeNewswire Inc. • 01/30/2024 09:15:00 PM
- Royalty Pharma Announces Dividend Increase • GlobeNewswire Inc. • 01/19/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:18:52 PM
- Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:31:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/03/2024 09:30:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:29:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 06:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:30:29 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM